Loading…
← CockpitCompetitor Analysis › PPGN.SW PolyPeptide Group AGOpen in the cockpit ↗

PolyPeptide Group AGPPGN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Biotechnology

Swiss contract manufacturer (CDMO) that makes peptide-based drug ingredients, including for GLP-1 obesity/diabetes drugs.

≈ A peptide-manufacturing CDMO like a smaller Bachem HoldingMomentum weak 27
Mkt cap
$1.61B
US dollars, full cap
Free float
35%
of shares outstanding
$/day
$759,644
20-day average traded
Fwd P/E
52.1×
forward earnings
ROIC−WACC
-0.3 pp
WACC 6.3%
Hurdle
n/a
no reverse DCF
Next earnings
111 days
9 Mar 2027
Close · CHFCHF 41.05
1D+2.0%
1W+1.6%
1M-6.8%
3M-6.6%
6M+7.3%
YTD+57.3%
1Y+72.8%
ATR %1.6%
52w lowhigh18.1% off high

What PolyPeptide does

Swiss contract manufacturer (CDMO) that makes peptide-based drug ingredients, including for GLP-1 obesity/diabetes drugs.

Is paid for development work and for manufacturing batches of peptide ingredients under supply agreements, with a few big customers accounting for much of the volume, so one customer's order shift can sway a year. Its sites in Europe and the US supply both clinical and commercial drugs.

In one line: A peptide-manufacturing CDMO like a smaller Bachem Holding.

Products and services

  • Peptide API contract manufacturing
  • Peptide process development

Customers

  • Pharmaceutical companies (drug sponsors, e.g. GLP-

Where it sits in the supply chain

  • Health Care
  • Pharmaceutical manufacturing (CDMO)
  • Peptide active pharmaceutical…

What could go right

  • GLP-1/obesity drug manufacturing demand boom
  • New customer contract wins

What could go wrong

  • Customer/drug concentration risk
  • Capital-intensive capacity expansion costs

Moat: narrow (process know-how, regulatory licence, scale). Specialized peptide synthesis capacity and regulatory-approved manufacturing are scarce amid surging GLP-1 drug demand.

Headquarters: Zug, Switzerland · Founded: 1996 · Employees: 1,469

Named competitors

PolyPeptide at a glance

Size PolyPeptide (PPGN.SW) is a Switzerland Health Care company (Biotechnology) with a market value of $1.61B, the 103rd largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 41.05 on 18 Nov 2026.

Performance Over six months the shares gained 7.3%, against -12.8% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 22.1% over the last twelve months (peer median +33.8%); the operating margin is 7.0% (peer median -6.3%).

Valuation It trades at 52.1× forward earnings against a peer median of 20.4× (2nd most expensive of 9).

Capital Return on invested capital runs 0.3 points below its cost of capital (6.3% WACC).

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026PPGN.SW 110Peer median 86
Six months, rebased to 100: PolyPeptide against the median of its 20 peers (local-currency closes).

PolyPeptide financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 424MCHF 365MCHF 321MCHF 311MCHF 282M
Revenue growth—+14%+3%+10%—
Gross profitCHF 95.9MCHF 59.9MCHF 34.4MCHF 3.12MCHF 50.9M
EBITDACHF 73.1MCHF 41.4MCHF 22.3M-CHF 10.2MCHF 36.3M
Net incomeCHF 13.3M-CHF 19.8M-CHF 18.6M-CHF 50.0MCHF 7.80M
Free cash flow-CHF 46.1M-CHF 28.3MCHF 3.48M-CHF 15.9M-CHF 69.9M
Capital expenditureCHF 96.0MCHF 102MCHF 82.8MCHF 55.1MCHF 79.1M
Total debtn/aCHF 121MCHF 88.3MCHF 106MCHF 21.0M

Quarterly statements and history in the cockpit →

PolyPeptide competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%6949688222ALVOANIP600226VIRNRIXPGENKLRA145020KRSA087010MSB2637RXRXURGN688765PPGN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. PolyPeptide is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%20×40×60×688222ALVOANIP600226PGEN1450202637URGNPPGN.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PolyPeptide is the large dot.

PolyPeptide competitors and peer comparison

Head to head with its named competitors (PPGN.SW vs BANB.SW vs LONN.SW vs 2359.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
PolyPeptide PPGN.SW$1.61B+7%+22%7%52.1×n/a
Bachem BANB.SW$7.06B0%+5%19%32.4×n/a
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%

How PolyPeptide compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PolyPeptide against its 20 peers (data as of 18 Nov 2026)
MeasurePPGN.SWPeer medianRank in peer set
1-month return-6.8%-9.9%8th highest of 21
6-month return+7.3%-12.8%4th highest of 20
Distance from 52-week high-18.1%-45.0%highest of 21
Revenue growth (TTM)+22.1%+33.8%8th lowest of 19
Operating margin7.0%-6.3%9th highest of 19
Forward P/E52.1×20.4×2nd most expensive of 9
ROIC minus cost of capital-0.3 pp-10.8 pp5th highest of 15
EV / EBITDA19.5×8.5×3rd most expensive of 6
Net debt / EBITDA1.0×-1.1×3rd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%52.1×n/an/a
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%n/an/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%73.2×33.2%+16.8%
Alvotech ALVOUnited States$1.62B+38%-14%12%22.6×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%7.5×-7.6%+33.5%
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%27.6×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%n/an/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%n/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%7.3×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%18.1×-12.1%+15.0%
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%n/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%n/an/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%n/an/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%n/an/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%16.7×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%n/an/an/a

Questions

Who are PolyPeptide's main competitors?
Named competitors: Bachem Holding (BANB.SW), Lonza Group (LONN.SW), WuXi STA (WuXi AppTec) (2359.HK). The cockpit's measured peer set (industry) also includes PELL Bio-Med Technology (6949.TW), Hitgen (688222.SS), Alvotech (ALVO), ANI Pharmaceuticals (ANIP), Zhejiang Hengtong (600226.SS), Vir Biotechnology (VIR).
Is PolyPeptide expensive compared with its peers?
On forward p/e it trades at 52.1× against a peer median of 20.4×, 2nd most expensive of 9 in its peer set.
How has PolyPeptide stock performed?
Over six months to 18 Nov 2026 the shares returned +7.3% against -12.8% for the median peer; over one year +72.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.